Zacks Research upgraded Anixa Biosciences from a hold to a strong-buy recommendation.
The upgrade follows the clinical-stage immuno-oncology company reporting a smaller-than-expected loss in its latest quarterly results. Analysts established a consensus price target of $8.50 for the stock.
Anixa Biosciences develops cell-based immunotherapies and vaccine platforms targeting cancer and infectious diseases.